Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Salbutamol is a β2 adrenergic agonist widely prescribed in patients with obstructive and restrictive lung diseases. The main side effects associated with its use are tachycardia and tremor. Myoclonus is an involuntary, irregular, abrupt, brief and sudden muscular contraction, which can be generalized, focal or multifocal. We report the case of a 61-year-old patient presenting with myoclonus difficult to treat who showed improvement only after the definitive discontinuation of the β2 adrenergic agonist. We describe the clinical findings, the interventions, and the outcomes related to the onset of myoclonus secondary to the use of salbutamol, as well as the possible genesis and importance of this adverse effect. We used the CARE guidelines to delineate the clinical case. Although myoclonus secondary to the use of different drugs has been described in the literature, as far as we know this is the fourth report of salbutamol-induced myoclonus to date.

Original publication






Publication Date





303 - 307


albuterol, Myoclonus, pharmacovigilance, drug-related side effects and adverse reactions, pharmacology, toxicology, Adrenergic beta-2 Receptor Agonists, Albuterol, Combined Modality Therapy, Drug Synergism, Drug Therapy, Combination, Emergencies, Fatal Outcome, Fenoterol, Humans, Ipratropium, Male, Methylprednisolone, Middle Aged, Myoclonus, Oxygen Inhalation Therapy, Pulmonary Disease, Chronic Obstructive, Substance-Related Disorders